JOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014
|
|
- Valentine Hunter
- 5 years ago
- Views:
Transcription
1 HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research Fellow, Dept. of Orthopaedic Surgery, King George Medical University, Lucknow, India 2 Professor & Head, Dept. of Orthopaedic Surgery, King George Medical University, Lucknow, India 3 Professor & Head, Dept. of Physical Medicine & Rehabilitation, King George Medical University, Lucknow, India 4 Professor, Dept. of Obstretics and Gynaecology, King George Medical University, Lucknow, India 5 Professor & Head, Dept. of Biochemistry, King George Medical University, Lucknow, India 6 Professor, Dept. of Orthopaedic Surgery, King George Medical University, Lucknow, India ABSTRACT Vitamin D is a fat soluble hormone that plays a vital role in calcium homeostasis. Estrogen increases serum levels of 1,25 (OH )2D and calcium, thereby affecting calcium metabolism.due to deficiency of estrogen after menopause in females, there is increase in osteoclastic cell activity resulting in decrease bone quality and bone mineral density. We carried out this cross sectional cohort study to find out the prevalence of Vit D in postmenopausal women having low bone mineral density. Total 128 females with established menopause were enrolled in study. All female had osteoporosis of at least one side either at spine, hip or at forearm. 25(OH)D level in the serum were measured in all patients by chemiluminiscence immunoassay and graded into three groups as Vitamin D deficiency( < 20ng/ml), Vitamin D insufficiency(21 29ng/ml), and sufficiency(30 100ng/ml). The results are presented in means and percentages. All the analysis was carried out by using SPSS 16.0 version. A total of 128 females were included in the study with mean age of (±4.80) years and range between 45 to 65 years. The average no. of years since menopause was 6.05 (±4.31) years. Out of 128 subjects only 21(16.45%) subjects had sufficient level of Vit D, 40 (31.2%) subjects had insufficient Vit D level and rest 67 (52.3%)subjects had deficient Vit D level. There is high prevalence of Vit D deficiency among post menopausal osteoporotic females as only less than a quarter of our patients have adequate Vit D level, we recommend that all post menopausal female with osteoporosis should undergo evaluation and treatment for Vit D deficiency for the optimum management of osteoporosis. KEYWORDS: Post Menopausal Osteoporosis, Vitamin D Deficiency, Vitamin D Insufficiency, Vitamin D Sufficiency 448
2 INTRODUCTION Vitamin D3 (Cholecalciferol) is synthesized in the skin, from 7 dehydro-cholesterol in the presence of UVB rays. Cholecalciferol undergo further hydroxylation in the liver and subsequently in kidney to convert into the active form 1,25 dihydroxy cholecalciferol responsible for a multitude of its effects(1). There is the recent surge in the literature regarding vitamin D and its correlation to multiple diseases, because of its anti-inflammatory and immune-modulating properties, it has been linked to cardiovascular disease, diabetes, skin cancer, multiple sclerosis, cognition disorder apart from musculoskeletal disorders(1,2). Vitamin D (Vit D) is a fat soluble hormone that plays a vital role in calcium homeostasis. Due to deficiency of Vit D, there is a decrease in absorption of calcium from the intestine resulting in a decrease level of serum ionized calcium and up regulation of parathyroid gland, causing secondary hyperparathyroidism. Secondary hyperparathyroidism increases serum calcium by mobilizing bone calcium, results in bone loss(3). Postmenopausal osteoporosis in females is due to deficiency of estrogen following either due to surgical or natural menopause. Estrogen is responsible for controlling osteoclastic cell activity and bone health. Due to deficiency of estrogen there is increase in the number of osteoclast cell and osteoclastic activity. Estrogen increases serum 1,25 (OH )2D by stimulating renal 1-hydroxylase enzyme,thereby help in maintaing calcium homeostasis and bone turn over metabolism, so in postmenopausal osteoporosis due to deficiency of estrogen there is also decline in the level of active Vit D(4). We carried out this cross sectional cohort study to find out the prevalence of Vit D in postmenopausal women having low bone mineral density. Methods & Material: Total 128 females were recruited from outdoor department of Orthopaedic surgery and Obstetrics and gynaecology, in study. All bio-chemical analysis were done in department of Biochemistry. Informed consent was taken from each patient and ethical clearance was approved by Institutional Ethical Committee. All female had menopause, with minimum one year passed from the cessation of menstruation and they had osteoporosis of at least one side either at spine, hip or at forearm as per bone mineral density(bmd) done by Dual Energy X- ray Absorptiometry (DEXA) scan. All patients were classified according to WHO grading system in normal, osteopenic and osteoporosis depending upon their T scores(5). Patients having systemic metabolic disorder like liver disorder, renal dysfunction and intestinal malfunction affecting calcium and Vit D metabolism,malignancy, thyroidism and hyperparathyroidism were excluded. Patients who were previously treated for Vit D 449
3 deficiency or having any long term medication were also excluded. 25(OH)D level in the serum were measured in all patients by chemiluminiscence immunoassay. Patients were graded into three groups as Vitamin D deficiency if level of 25(OH)D less than 20ng/ml, Vitamin D insufficiency if level of 25(OH)D found between 21 29ng/ml, and sufficiency if level of 25(OH)D found between ng/ml(2,6). Statistical analysis: The results are presented in means and percentages. The one way analysis of variance (ANOVA) was used to compare the vitamin D level and BMD among normal, osteopenia and osteoporosis. The Tukey s post hoc multiple comparison test was used to compare between two groups which were found to be statistically significant in ANOVA at p<0.05. The unpaired t-test was used to compare vitamin D level and BMD between two groups. The p- value <0.05 was considered significant. All the analysis was carried out by using SPSS 16.0 version (Chicago, Inc., USA). Results: A total of 128 females were included in the study with mean age of (±4.80) years and range between 45 to 65 years. The average no. of years since menopause was 6.05 (±4.31) years. Out of 128 subjects only 21(16.45%) subjects had sufficient level of Vit D, 40 (31.2%) subjects had insufficient Vit D level and rest 67 (52.3%)subjects had deficient Vit D level(fig-1). Fig.1: Vitamin D status among all the women Mean bone mineral density in 128 patients with osteoporosis at spine was 0.73±0.12,at hip 0.62±0.07 and at left forearm 0.58±0.16.Mean T score in 128 patients with osteoporosis at spine was -3.76±0.97,at left hip -2.9±0.53,at right hip -2.96±0.57 and at left forearm- 3.5±1.7.There was no significant difference in the vitamin D level among patients having either normal, osteopenia or osteoporosis at spine,hip and forearm region(table-1). 450
4 Table:1 Comparison of Vitamin D levels between different groups Vitamin D level p-value 1 (Mean±SD) Normal Osteopenia Osteoporosis T-spine 22.80± ± ± a Neck 23.30± ± ± a Forearm 26.50± ± ± b a Unpaired t-test between Osteopenia and Osteoporosis, b ANOVA test DISCUSSION Vit D deficiency is a global health problem and it is widely prevalent in India affecting all age groups(2). We observed high prevalence of Vit D deficiency in post menopausal osteoporotic patients in our study. We found only 16.45% patients had sufficient Vit D levels, 31% had insufficient Vit D levels and rest 52% had deficient Vit D levels. Sufficient Vit D levels signifies that serum 25(OH )D level is above 30ng/ml, at this level intestinal absorption of calcium is optimum under Vit D action and level of parathyroid hormone falls in serum, thus preventing secondary hyperparathyroidism, responsible for mobilizing bone calcium into serum. At level below 20 ng/ml, there is decrease calcium absorption from gut and increase in parathyroid level resulting into secondary hyperparathyroidism and further bone loss(2,7). Narula et al(8) in his study on post menopausal osteoporotic females reported that 62% females were having deficient Vit D levels. Harinarayan et al(9) reported higher prevalence, 70% post menopausal females subjects had deficient Vit D levels and 23% subjects had insufficient level. Osteoporosis occur due to imbalance in bone turn over metabolism,characterized by increase osteoclastic activity in comparison to osteoblastic activity, resulting into detoriation of bone quality and decrease in bone mineral density. Vit D plays an integral role in bone turnover metabolism by affecting calcium and parathyroid hormone activity. In postmenopausal osteoporosis, due to deficiency of estrogen, there is decrement in the level of active 1,25 (OH )2D because of less stimulation of renal 1-hydroxylase enzyme, results into decrease calcium absorption from gut and consequently secondary hyperparathyroidism(4). Post menopausal osteoporosis can be effectively treated by early diagnosis and treatment by biphosphonate, calcium and Vit D supplementation(7,9,10). In our study we treated our subjects with weekly or monthly biphosphonate,1250 mg calcium per day and 60,000 IU of vitamin D weekly for ten weeks followed by maintenance dose of 1000 IU per day. 451
5 CONCLUSION There is high prevalence of Vit D deficiency among post menopausal osteoporotic females as only less than a quarter of our patients have adequate Vit D level, we recommend that all post menopausal female with osteoporosis should undergo evaluation and treatment for Vit D deficiency for the optimum management of osteoporosis. Conflict of Intrest: None REFERENCES 1. Kulie T, Groff A, Redmer J, Hounshell J, Schrager S. Vitamin D: An Evidence-Based Review. J Am Board Fam Med 2009;22: Ritu G, Gupta A.Vitamin D Deficiency in India: Prevalence, Causalities and Interventions. Nutrients 2014, 6, Gallagher JC, Riggs BL, DeLuca HF.Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis. J Clin Endocrinol Metab Dec; 51 (6): Sipos W, Pietschmann P, Rauner M, Schindl K K, Patsch J.Pathophysiology of osteoporosis. Wien Med Wochenschr (2009) 159/9 10: Kanis JA. (1994). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int., 4(6): Holick MF.Optimal vitamin D status for the prevention and treatment of osteoporosis. Drugs Aging. 2007;24(12): Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM; AACE Osteoporosis Task Force.American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract Nov-Dec;16 Suppl 3: Narula R, Mujtaba T, Iraqi A A, Agarwal K, Agarwal A, Arya A. Vitamin D Deficiency Among Postmenopausal Women with Osteoporosis Journal of Clinical and Diagnostic Research February, Vol-7(2): Harinarayan Cv, Alok Sachan, P. Amaresh reddy, et al. vitamin D status and bone mineral Density in Women of reproductive and Postmenopausal age groups: A cross-sectional study from South India. J Assoc Physicians India 2011;59: Frederick T. Murphy,Alan J. Kivitz, Earl E. Sands,Management of Postmenopausal Osteoporosis. J Am Osteopath Assoc October 2003;103( 6 ): Delmas PD.Treatment of postmenopausal osteoporosis. Lancet 2002; 359:
Skeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationVitamin D Replacement ROCKY MOUNTAIN MEETING NOV 2013 BANFF W.COKE UNIVERSITY OF TORONTO
Vitamin D Replacement ROCKY MOUNTAIN MEETING NOV 2013 BANFF W.COKE UNIVERSITY OF TORONTO Disclosures: (Academic Mea Culpa) No financial conflicts I have no expertise re: Vitamin D. OBJECTIVES: 1) Review
More informationVitamin D. Vitamin functioning as hormone. Todd A Fearer, MD FACP
Vitamin D Vitamin functioning as hormone Todd A Fearer, MD FACP Vitamin overview Vitamins are organic compounds that are essential in small amounts for normal metabolism They are different from minerals
More informationVitamin D. Mrs Sophie Barnes FRCPath Consultant Clinical Scientist
Vitamin D Mrs Sophie Barnes FRCPath Consultant Clinical Scientist Learning objectives Biochemistry and physiology of vitamin D Causes and consequences of vitamin D deficiency Current and anticipated guidelines
More informationJMSCR Vol 04 Issue 12 Page December 2016
www.jmscr.igmpublication.org Impact Factor 5.244 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v4i12.27 The Prevalence of Osteoporosis and Osteopenia
More informationThe Role of the Laboratory in Metabolic Bone Disease
The Role of the Laboratory in Metabolic Bone Disease Howard Morris PhD, FAACB, FFSc(RCPA) President, IFCC Professor of Medical Sciences, University of South Australia, Clinical Scientist, SA Pathology
More informationOSTEOMALACIA UPDATE. Nothing to Disclose. Daniel D Bikle, MD, PhD Professor of Medicine University of California and VA Medical Center San Francisco
OSTEOMALACIA UPDATE Daniel D Bikle, MD, PhD Professor of Medicine University of California and VA Medical Center San Francisco Nothing to Disclose 1 Case History 59 YO WM referred for evaluation of diffuse
More informationElecsys bone marker panel. Optimal patient management starts in the laboratory
bone marker panel Optimal patient management starts in the laboratory Complete solution for osteoporosis The most complete bone metabolism panel on a single platform bone marker assays are important diagnostic
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationBone (Mineral) Density Studies
Bone (Mineral) Density Studies Policy Number: Original Effective Date: MM.05.002 03/23/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2014 Section: Radiology Place(s) of Service:
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationCalcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More informationUpdate on vitamin D. J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska USA
Update on vitamin D J Chris Gallagher Professor of Medicine and Endocrinology Creighton University Omaha,Nebraska 68131 USA Cali, Colombia 2016 definitions DRIs are the recommended dietary reference intakes
More informationHyperparathyroidism: Operative Considerations. Financial Disclosures: None. Hyperparathyroidism. Hyperparathyroidism 11/10/2012
Hyperparathyroidism: Operative Considerations Financial Disclosures: None Steven J Wang, MD FACS Associate Professor Dept of Otolaryngology-Head and Neck Surgery University of California, San Francisco
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More informationCorrelation between Thyroid Function and Bone Mineral Density in Elderly People
IBBJ Spring 2016, Vol 2, No 2 Original Article Correlation between Thyroid Function and Bone Mineral Density in Elderly People Ali Mirzapour 1, Fatemeh Shahnavazi 2, Ahmad Karkhah 3, Seyed Reza Hosseini
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationVitamin D Hormone Du Jour
Vitamin D Hormone Du Jour J R Minkoff MD, FACP Endocrinology Clinical Professor of Family and Community Medicine UCSF Why Is Vitamin D Important? Musculo-skeletal effects Possible other effects Immunomodulatory
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationJMSCR Vol 06 Issue 12 Page December 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i12.157 A comparative study of two
More informationBone Health in Celiac Disease. Partha S. Sinha MD, PhD October 29 th, 2017
Bone Health in Celiac Disease Partha S. Sinha MD, PhD October 29 th, 2017 No Disclosures Objectives Recognize the mechanisms by which celiac disease can affect bone health Review what diagnostic tests
More informationEndocrine Regulation of Calcium and Phosphate Metabolism
Endocrine Regulation of Calcium and Phosphate Metabolism Huiping Wang ( 王会平 ), PhD Department of Physiology Rm C516, Block C, Research Building, School of Medicine Tel: 88208252 Email: wanghuiping@zju.edu.cn
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationBone Mineral Density and Its Associated Factors in Naresuan University Staff
Naresuan University Journal 2005; 13(3): 13-18 13 Bone Mineral Density and Its Associated Factors in Naresuan University Staff Supawitoo Sookpeng *, Patsuree Cheebsumon, Malinee Dhanarun, Thanyavee Pengpan
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationObjectives. Discuss bone health and the consequences of osteoporosis on patients medical and disability status.
Objectives Discuss bone health and the consequences of osteoporosis on patients medical and disability status. Discuss the pathophysiology of osteoporosis and major risk factors. Assess the major diagnostic
More informationTREATMENT OF OSTEOPOROSIS
TREATMENT OF OSTEOPOROSIS Summary Prevention is the key issue in the management of osteoporosis. HRT is the agent of choice for prevention of postmenopausal osteoporosis. Bisphosphonates and Calcitonin
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationDisclosure and Conflicts of Interest Steven T Harris MD Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis
Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis Steven T Harris MD FACP Clinical Professor of Medicine University of California, San Francisco Disclosure and Conflicts of Interest
More informationCan we improve the compliance to prevention treatment after a wrist fracture? Roy Kessous
Can we improve the compliance to prevention treatment after a wrist fracture? Roy Kessous Distal radius fracture in women after menopause is in many cases a first clinical indication for the presence of
More informationDEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN
October 2-4, Liverpool, UK EURO SPINE 2013 DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN D. Colangelo, L. A. Nasto, M. Mormando, E.
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationDiscovering prior fractures in your postmenopausal patient may be the LINK to reducing her fragility fracture* risk in the future.
Discovering prior fractures in your postmenopausal patient may be the LINK to reducing her fragility fracture* risk in the future. *A fragility fracture is defined as a fracture caused by minimal trauma,
More informationA Case of Cushing Syndrome Diagnosed by Recurrent Pathologic Fractures in a Young Woman
A Case of Cushing Syndrome Diagnosed by Recurrent Pathologic Fractures in a Young Woman JY Han, et al CASE REPORT http://dx.doi.org/10.11005/jbm.2012.19.2.153 Vol. 19, No. 2, 2012 A Case of Cushing Syndrome
More informationVitamin D Deficiency in Patients presented in Medical OPD with Fibromyalgia Muhammad Arif Mahmood, Muhammad Arshad Qureshi, Ijaz-Ul-Haque Taseer
Original Article Vitamin D Deficiency in Patients presented in Medical OPD with Fibromyalgia Muhammad Arif Mahmood, Muhammad Arshad Qureshi, Ijaz-Ul-Haque Taseer ABSTRACT Objectives: To determine the prevalence
More informationBone Densitometry Pathway
Bone Densitometry Pathway The goal of the Bone Densitometry pathway is to manage our diagnosed osteopenic and osteoporotic patients, educate and monitor the patient population at risk for bone density
More informationOMICS Journals are welcoming Submissions
OMICS Journals are welcoming Submissions OMICS International welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationOSTEOPOROSIS AND WHAT TO DO AFTER A VERTEBRAL FRACTURE. Lydia Au Geriatrics Ng Teng Fong Hospital
OSTEOPOROSIS AND WHAT TO DO AFTER A VERTEBRAL FRACTURE Lydia Au Geriatrics Ng Teng Fong Hospital LET S START WITH WHAT YOU WANT TO KNOW AND DO WITH A VERT FRACTURE Vertebral fractures Most common (550K
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Osteoporosis- Do We Need to Think Beyond Bone Mineral Density? Dr Preeti Soni 1, Dr Shipra
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationHyperparathyroidism. When to Suspect, How to Diagnose, When and How to Intervene. Johanna A. Pallotta, MD, FACP, FACE
Hyperparathyroidism When to Suspect, How to Diagnose, When and How to Intervene Johanna A. Pallotta, MD, FACP, FACE Potential conflicts of interest: None Johanna A. Pallotta, MD Outline Definition of hyperparathyroidism
More informationUnderstanding the Development of Osteoporosis and Preventing Fractures: WHO Do We Treat Now?
Understanding the Development of Osteoporosis and Preventing Fractures: WHO Do We Treat Now? Steven M. Petak, MD, JD, FACE, FCLM Texas Institute for Reproductive Medicine And Endocrinology, Houston, Texas
More informationThe discovery of Vitamin D and the elimination of rickets has been considered as one of Medicine s Greatest Achievements.
The discovery of Vitamin D and the elimination of rickets has been considered as one of Medicine s Greatest Achievements. SIR EDWARD MELLANBY 1 8 8 4-1 9 5 5 A D I E T C H A R A C T E R I S T I C O F S
More informationEffects of vitamin D deficiency and daily calcium intake on bone mineral density and osteoporosis in Korean postmenopausal woman
Original Article Obstet Gynecol Sci 2017;60(1):53-62 https://doi.org/10.5468/ogs.2017.60.1.53 pissn 2287-8572 eissn 2287-8580 Effects of vitamin D deficiency and daily calcium intake on bone mineral density
More informationForearm bone mineral density in postmenopausal Indian women: correlation with calcium nutrition
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Sharma S et al. Int J Reprod Contracept Obstet Gynecol. Oct;():- www.ijrcog.org DOI: http://dx.doi.org/./-.ijrcog pissn -
More informationVitamin D Deficiency. Decreases renal calcium excretion. Increases intestinal absorption Calcium. Increases bone resorption of calcium
Vitamin D Deficiency Deborah Gordish, MD Assistant Professor of Clinical Internal Medicine Lead Physician Lewis Center Primary Care Associate Division Director General Internal Medicine The Ohio State
More informationEffect of a Short-Term Treatment with Once-A-Week Medication of Alendronate 70 Mg on Bone Turnover Markers in Postmenopausal Women with Osteoporosis
Effect of a Short-Term Treatment with Once-A-Week Medication of Alendronate 70 Mg on Bone Turnover Markers in Postmenopausal Women with Osteoporosis Likit Rugpolmuang MD*, Saranatra Waikakul MD* * Department
More informationEfficacy, Side Effects, Safety and Effects on Bone Turnover Markers of once a Week Sandoz Alendronate Sodium Trihydrate 70 mg
doi: 10.5704/MOJ.1107.004 Efficacy, Side Effects, Safety and Effects on Bone Turnover Markers of once a Week Sandoz Alendronate Sodium Trihydrate 70 mg Waikakul S, MD, FRCOST, Sintuvanich N, MD, Assanasuwan
More informationEmerging Areas Relating Vitamin D to Health
ILSI SEA Region Vit D Conference, Australia, June 2012 (www.ilsi.org/sea Region) Emerging Areas Relating Vitamin D to Health Peter R Ebeling MD FRACP NorthWest Academic Centre and Dept Endocrinology The
More informationInadequate Dietary Calcium and Vitamin D Intake in Patients with Osteoporotic Fracture
J Bone Metab 2016;23:55-61 http://dx.doi.org/10.11005/jbm.2016.23.2.55 pissn 2287-6375 eissn 2287-7029 Original Article Inadequate Dietary Calcium and Vitamin D Intake in Patients with Osteoporotic Fracture
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationEffect of Precision Error on T-scores and the Diagnostic Classification of Bone Status
Journal of Clinical Densitometry, vol. 10, no. 3, 239e243, 2007 Ó Copyright 2007 by The International Society for Clinical Densitometry 1094-6950/07/10:239e243/$32.00 DOI: 10.1016/j.jocd.2007.03.002 Original
More informationDrug Intervals (Holidays) with Oral Bisphosphonates
Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate
More informationEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:
More informationBad to the bones: treatments for breast and prostate cancer
12 th Annual Osteoporosis: New Insights in Research, Diagnosis, and Clinical Care 23 rd July 2015 Bad to the bones: treatments for breast and prostate cancer Richard Eastell, MD FRCP (Lond, Edin, Ireland)
More informationSupplementary Information to Chapter 36
REVIEW ON VITAMIN-D NEW INSIGHTS Elmer Verner McCollum (1879-1967) was the first to discover the antirachitic vitamin which he named as vitamin D in the early part of 20th century (1919). He had earlier
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationVitamin D Supplementation for Pain
Vitamin D Supplementation for Pain Christan M. Thomas, PharmD; Peter Campbell, PharmD US Pharmacist. 2015;40(3):43 46. www.medscape.com Abstract and Introduction Abstract Vitamin D, a fat soluble vitamin
More informationORIGINAL ARTICLE SERUM OSTEOCALCIN, SHALL WE CONSIDER IT AS A BIOCHEMICAL MARKER FOR OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
SERUM OSTEOCALCIN, SHALL WE CONSIDER IT AS A BIOCHEMICAL MARKER FOR OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN V. S. Kalai Selvi 1, K. Prabhu 2, Monika Gupta 3. HOW TO CITE THIS ARTICLE: V. S. Kalai Selvi, K.
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationSession 4: New Evidence-Based Clinical Prac ce Guidelines B: Management of Osteoporosis in Post-Menopausal Women 4:15pm - 5:15pm
January 20-22, 2012 Des Moines Marrio, 700 Grand Avenue, Des Moines, IA Session 4: New Evidence-Based Clinical Prac ce Guidelines B: Management of Osteoporosis in Post-Menopausal Women 4:15pm - 5:15pm
More informationAromatase Inhibitors & Osteoporosis
Aromatase Inhibitors & Osteoporosis Miss Sarah Horn Consultant Oncoplastic Breast Surgeon April 2018 Aims Role of Aromatase Inhibitors (AI) in breast cancer treatment AI s effects on bone health Bone health
More informationBone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome
Bone Metabolism in Postmenopausal Women Influenced by the Metabolic Syndrome Thomas et al. Nutrition Journal (2015) 14:99 DOI 10.1186/s12937-015-0092-2 RESEARCH Open Access Acute effect of a supplemented
More informationDoes raloxifene (Evista) prevent fractures in postmenopausal women with osteoporosis?
FPIN's Clinical Inquiries Raloxifene for Prevention of Osteoporotic Fractures Clinical Inquiries provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationPrevalence Of Vitamin D Inadequacy In Peri And Postmenopausal Women Presented At Dow University Hospital, Ojha Campus. A Cross Sectional Study
ISPUB.COM The Internet Journal of Nutrition and Wellness Volume 12 Number 1 Prevalence Of Vitamin D Inadequacy In Peri And Postmenopausal Women Presented At Dow University S Shukar-ud-din, R Tabassum,
More informationStudy of secondary causes of male osteoporosis
Study of secondary causes of male osteoporosis Suárez, S.M., Giunta J., Meneses G., Costanzo P.R., Knoblovits P. Department of Endocrinology, Metabolism and Nuclear Medicine of Hospital Italiano of Buenos
More informationObjectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING
Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING TIFFANY PAUL, APN, CNP, CCD Objectives: Review the diagnosis of Osteoporosis Describe the basics of a bone density exam Identify
More informationChapter 39: Exercise prescription in those with osteoporosis
Chapter 39: Exercise prescription in those with osteoporosis American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:
More informationTymlos (abaloparatide)
Tymlos (abaloparatide) Policy Number: 5.01.638 Last Review: 11/2018 Origination: 10/2017 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Tymlos
More informationV t i amin i n D a nd n d Calc l iu i m u : Rol o e l in i n Pr P eve v nt n io i n and n d Tr T eatment n of o Fr F actur u es and n d Fa F ll l s
Vitamin D and Calcium: Role in Prevention and Treatment of Fractures and Falls Osteoporosis 21: New Insights In Research, Diagnosis, and Clinical Care Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic
More informationBone mineral density of patients attending a clinic in Dubai
Bone mineral density of patients attending a clinic in Dubai Freshteh Hosseini Dana 1, Faisal Al-shammari 1, Asma usadiq 1, Maryam Nurudeen Abdurahman 1, Golshid Lotfizadeh 1*, Shatha Al-Sharbatti 2, Rizwana
More informationComparison of the efficacy of three once-weekly bisphosphonates on bone mineral density gains in Korean women
Original Article Obstet Gynecol Sci 2013;56(3):176-181 http://dx.doi.org/10.5468/ogs.2013.56.3.176 pissn 2287-8572 eissn 2287-8580 Comparison of the efficacy of three once-weekly bisphosphonates on bone
More informationMEDICAL POLICY EFFECTIVE DATE: 08/21/14 REVISED DATE: 04/16/15, 06/16/16, 07/20/17 SUBJECT: SCREENING FOR VITAMIN D DEFICIENCY
MEDICAL POLICY SUBJECT: SCREENING FOR VITAMIN D DEFICIENCY A nonprofit independent licensee of the BlueCross BlueShield Association PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not
More informationK K MK-4 MK-4 1,25-D3
22 5 13 D 25-Hydroxyvitamin D Gla K K D K D K K K -4MK-4 MK-4 MK-4 steriod and xenobiotic receptorsxr MK-4 SXR MK-4 K MK-4 D 1,25-D3 D 1 CYP27B1CYP27B1-KO D CYP27B1-KO D D CYP27B1-KO Ca 1,25-D3 D Vitamin
More informationVitamin D: Is it a superhero??
Vitamin D: Is it a superhero?? Dr. Ashraf Abdel Basset Bakr Prof. of Pediatrics 1 2 History of vitamin D discovery Sources of vitamin D and its metabolism 13 Actions of vitamin D 4 Vitamin D deficiency
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationVITAMIN D IN HEALTH AND DISEASE
VITAMIN D IN HEALTH AND DISEASE Margus Lember University of Tartu, Estonia ESIM, Saas Fee, January 16, 2014 l It`s most healthy to live on the southern side of a mountain l Hippokrates of Kos 460-370 BC
More informationInternational Journal of Research and Review E-ISSN: ; P-ISSN:
International Journal of Research and Review www.gkpublication.in E-ISSN: 2349-9788; P-ISSN: 2454-2237 Original Research Article Risk Assessment of Osteoporosis in Postmenopausal Women Dr Savita Tamaria
More informationCa, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary
Ca, Mg metabolism, bone diseases Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Calcium homeostasis Ca 1000g in adults 99% in bones (extracellular with Mg, P) Plasma/intracellular
More informationKnowledge on Osteoporosis of Prescriber According to Level of Medical Institute
Original Article http://dx.doi.org/10.3349/ymj.2014.55.4.1058 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 55(4):1058-1062, 2014 Knowledge on Osteoporosis of Prescriber According to Level of Medical
More informationUniversity of Medicine and Pharmacy Craiova. Faculty of Medicine. PhD THESIS ABSTRACT
University of Medicine and Pharmacy Craiova Faculty of Medicine PhD THESIS ABSTRACT STUDY OF THE CHANGES IN BONE MASS AND BONE METABOLISM MARKERS IN THYROTOXIC OSTEOPOROSIS. THERAPEUTIC IMPLICATIONS. Scientific
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationHAART HIV & BONE METABOLISM HAART EDITORIAL. Bologna, April 5 th, 2013
HIV correlated pathologies and other infections HIV & BONE METABOLISM Bologna, April 5 th, 2013 Morning Session: Davide Gibellini, Fabio Vescini, Paolo Bonfanti, Stefano Mora, Antonio Di Biagio, Tiziana
More informationDM and Osteoporosis. Why is it important?
DM and Osteoporosis Why is it important? Diabetes Osteoporosis Fractures Dr Pedro Conthe HGUGM Madrid Spain Agenda: DM and Osteoporosis Observational studies Physiopathology of bone Type I and Type 2 DM
More informationName of Policy: Zoledronic Acid (Reclast ) Injection
Name of Policy: Zoledronic Acid (Reclast ) Injection Policy #: 355 Latest Review Date: May 2011 Category: Pharmacy Policy Grade: Active Policy but no longer scheduled for regular literature reviews and
More informationOsteoporosis is estimated to develop in 1 out of 4 women over the age of 50. Influence of bone densitometry results on the treatment of osteoporosis
Influence of bone densitometry results on the treatment of osteoporosis Nicole S. Fitt, * Susan L. Mitchell, * Ann Cranney, Karen Gulenchyn, Max Huang, * Peter Tugwell Abstract Background: Measurement
More informationCoordinator of Post Professional Programs Texas Woman's University 1
OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic
More informationManaging Endocrine Related Issues after Bariatric Surgery. Jenny Tong, MD, MPH Division of Endocrinology March 3, 2018
Managing Endocrine Related Issues after Bariatric Surgery Jenny Tong, MD, MPH Division of Endocrinology March 3, 2018 Bariatric Surgery was Associated with Higher Remission Rate than Usual Care 72.3% 38.1%
More information